Skip to main content
PMC home page
AAPS PharmSciTech logoLink to AAPS PharmSciTech
. 2003 Apr 30;4(2):147–156. doi: 10.1208/pt040228

Preparation and characterization of poly(D,L-lactide-co-glycolide) microspheres for controlled release of human growth hormone

Yilmaz Capan 1, Ge Jiang 2, Stefano Giovagnoli 3, Kyu-Heum Na 4, Patrick P DeLuca 5,✉
PMCID: PMC2750591  PMID: 12916910

Abstract

The purpose of this research was to assess the physicochemical properties of a controlled release formulation of recombinant human growth hormone (rHGH) encapsulated in poly(D,L-lactide-co-glycolide) (PLGA) composite microspheres. rHGH was loaded in poly(acryloyl hydroxyethyl) starch (acHES) microparticles, and then the protein-containing microparticles were encapsulated in the PLGA matrix by a solvent extraction/evaporation method. rHGH-loaded PLGA microspheres were also prepared using mannitol without the starch hydrogel microparticle microspheres for comparison. The detection of secondary structure changes in protein was investigated by using a Fourier Transfer Infrared (FTIR) technique. The composite microspheres were spherical in shape (44.6±2.47 μm), and the PLGA-mannitol microspheres were 39.7±2.50 μm. Drug-loading efficiency varied from 93.2% to 104%. The composite microspheres showed higher overall drug release than the PLGA/mannitol microspheres. FTIR analyses indicated good stability and structural integrity of HGH localized in the microspheres. The PLGA-acHES composite microsphere system could be useful for the controlled delivery of protein drugs.

Keywords: Microspheres, human growth hormone, protein delivery, composite microspheres

Full Text

The Full Text of this article is available as a PDF (440.1 KB).

References

  • 1.Woo BW, Jiang G, Jo YW, DeLuca PP. Preparation and characterization of a composite PLGA and poly(acryloyl hydroxyethyl starch) microsphere system for protein delivery. Pharm Res. 2001;18:1600–1606. doi: 10.1023/A:1013090700443. [DOI] [PubMed] [Google Scholar]
  • 2.Schrier JA, DeLuca PP. Recombinant human bone morphogenetic protein-2 binding and incorporation in PLGA microsphere delivery. Pharm Dev Technol. 1999;4:611–621. doi: 10.1081/PDT-100101400. [DOI] [PubMed] [Google Scholar]
  • 3.Okada HY, Heya IT, Ueno H, Ogawa Y, Toguchi H. Pharmacokinetics of once-a-month injectable microspheres of Leuprolide Acetate. Pharm Res. 1991;8:787–791. doi: 10.1023/A:1015818504906. [DOI] [PubMed] [Google Scholar]
  • 4.Hausberger G, DeLuca PP. Characterization of biodegradable poly (D,L-lactide-co-glycolide)polymers and microspheres. J Pharm Biomed Anal. 1995;13:747–760. doi: 10.1016/0731-7085(95)01276-Q. [DOI] [PubMed] [Google Scholar]
  • 5.Li X, Zhang Y, Yan R, et al. Influence of process parameters on the protein stability encapsulated in poly-DL-lactide-poly(ethylene glycol) microspheres. J Control Release. 2000;68:41–52. doi: 10.1016/S0168-3659(00)00235-2. [DOI] [PubMed] [Google Scholar]
  • 6.Sah H. Protein instability toward organic solvent/water emulsification: implications for protein microencapsulation into microspheres. PDA J Pharm Sci Technol. 1999;53:3–10. [PubMed] [Google Scholar]
  • 7.Johnson O, Cleland JL, Lee HJ, et al. A month-long effect from a single injection of microencapsulated human growth hormone. Nat Med. 1996;2:795–799. doi: 10.1038/nm0796-795. [DOI] [PubMed] [Google Scholar]
  • 8.Jorgensen JOL. Human growth hormone replacement therapy: pharmacological and clinical aspects. Endocr Rev. 1991;12:189–207. doi: 10.1210/edrv-12-3-189. [DOI] [PubMed] [Google Scholar]
  • 9.Moller J, Frandsen E, Fisker S, Jorgensen JO, Christiansen JS. Decreased plasma and extracellular volume in growth hormone deficient adults and the acute and prolonged effects of GH administration: a controlled experimental study. Clin Endocrinol. 1996;44:533–539. doi: 10.1046/j.1365-2265.1996.728550.x. [DOI] [PubMed] [Google Scholar]
  • 10.Fine RN, Kohaut EC, Brown D, Perlman AJ. Growth after recombinant growth hormone treatment in children with chronic renal failure: report of a multicenter randomized double-blind placebo-controlled study. Genentech Cooperative Study Group. J Pediatrics. 1994;124:374–382. doi: 10.1016/S0022-3476(94)70358-2. [DOI] [PubMed] [Google Scholar]
  • 11.Ranke MB. Growth Hormone therapy in Turner syndrome: analysis of long term results. Horm Res. 1995;44:35–41. doi: 10.1159/000184672. [DOI] [PubMed] [Google Scholar]
  • 12.Weintroth SE, Parenti DM, Simon GL. Wasting syndrome in AIDS: pathophysiologic mechanisms and therapeutic approaches. Infect Agents Dis. 1995;4:76–94. [PubMed] [Google Scholar]
  • 13.Cleland JL, Jonson OL, Putney S, Jones AJS. Recombinant human growth hormone poly(lactic-co-glycolic acid) microsphere formulation development. Adv Drug Deliv Rev. 1997;28:71–84. doi: 10.1016/S0169-409X(97)00051-3. [DOI] [PubMed] [Google Scholar]
  • 14.Wang N, Wu XS. A novel approach to stabilization of protein drugs in poly (lactide-co-glycolide) microspheres using agarose hydrogel. Int J Pharm. 1998;166:1–14. doi: 10.1016/S0378-5173(97)00339-6. [DOI] [Google Scholar]
  • 15.Pitt CG, Cha Y, Shah SS, Zhu KJ. Blends of PVA and PLGA: control of permeability and degradability of hydrogels by blending. J Control Release. 1992;19:189–200. doi: 10.1016/0168-3659(92)90076-4. [DOI] [Google Scholar]
  • 16.Huang LK, Mehta RC, Luca PP. Evaluation of a statistical model for the formation of poly(acryloyl hydroxyethyl starch) microspheres. Pharm Res. 1997;14:475–482. doi: 10.1023/A:1012199500072. [DOI] [PubMed] [Google Scholar]
  • 17.Cleland JL, Jones AJ. Stable formulation of recombinant human growth hormone and interferon-gamma for microencapsulation in biodegradable microspheres. Pharm Res. 1996;13(10):1464–1475. doi: 10.1023/A:1016063109373. [DOI] [PubMed] [Google Scholar]
  • 18.Shibuya T, Watanade Y, Nalley KA, Fusco A, Salafsky B. The BCA proteind etermination system: an analysis of several buffers, incubation temperature and protein standards. J Tokyo Mid College. 1989;47:677–682. [Google Scholar]
  • 19.Kang F, Singh J. Effect of additives on the release of a model protein from PLGA microspheres. AAPS Pharm Sci Tech. y2001;2(4) article 30. [DOI] [PMC free article] [PubMed]
  • 20.Prestrelski SJ, Tedeschi N, Arakawa T, Carpenter JF. Dehydration-induced conformational changes in proteins and their inhibition by stabilizers. Biophys J. 1993;65:661–671. doi: 10.1016/S0006-3495(93)81120-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Yang TH, Dong A, Meyer J, Johnson OL, Cleland JL, Carpenter JF. Use of infrared spectroscopy to assess secondary structure of Human Growth Hormone within biodegradable microspheres. J Pharm Sci. 1999;88(2):161–165. doi: 10.1021/js980423n. [DOI] [PubMed] [Google Scholar]
  • 22.Griebenow K, Klibanov AM. On protein denaturation in aqueous-organic mixtures but not in pure organic solvents. J Am Chem.Soc. 1996;118:11695–11700. doi: 10.1021/ja961869d. [DOI] [Google Scholar]
  • 23.Griebenow K, Klibanov AM. Can conformational changes be responsible for solvent and excipients effects on the catalytic behavior of subtilisin Carlsberg in organic solvents? Biotechnol Bioeng. 1997;53:351–362. doi: 10.1002/(SICI)1097-0290(19970220)53:4<351::AID-BIT1>3.0.CO;2-M. [DOI] [PubMed] [Google Scholar]
  • 24.Susi H, Byler DM. Resolution enhanced Fourier transform infrared spectroscopy of enzymes. Methods Enzymol. 1986;130:290–311. doi: 10.1016/0076-6879(86)30015-6. [DOI] [PubMed] [Google Scholar]
  • 25.Carrasquillo KG, Costantino HR, Cordero RA, Hsu CC, Griebenow K. On the structural preservation of recombinant human growth hormone in a dried film of a synthetic biodegradable polymer. J Pharm Sci. 1999;88(2):166–173. doi: 10.1021/js980272o. [DOI] [PubMed] [Google Scholar]
  • 26.Costantino HR, Carrasquillo KG, Cordero RA, Mumenthaler M, Hsu CC, Griebenow K. Effect of excipients on the stability and structure of lyophilized recombinant human growth hormone. J Pharm Sci. 1998;87(11):1412–1420. doi: 10.1021/js980069t. [DOI] [PubMed] [Google Scholar]

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists

RESOURCES